LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

Home・Listă Acțiuni・Incyte Corp
Search

Incyte Corp

Închisă

SectorSănătate

97.03

Cumpărare

Preț actualizat 26 mai 2026, 19:59 UTC

CumpărăVinde

Rezumat

Modificarea prețului

24h

Curent

Minim

96.01

Maxim

97.89

Indicatori cheie

By Trading Economics

Venit

4.1M

303M

Vânzări

-234M

1.3B

P/E

Medie Sector

13.445

49.701

EPS

1.81

Marjă de profit

23.834

Angajați

2,844

EBITDA

-47M

367M

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+11.46% upside

Dividende

By Dow Jones

Următoarele câștiguri

28 iul. 2026

Statistici piață

By TradingEconomics

Capitalizare de piață

-31M

19B

Deschiderea anterioară

97.03

Închiderea anterioară

97.03

Sentimentul știrilor

By Acuity

43%

57%

131 / 345 Clasament în Healthcare

Incyte Corp Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

25 mai 2026, 08:24 UTC

Principalele dinamici ale pieței
Achiziții, Fuziuni, Preluări

Uber's $11.6 Billion Takeover Approach Lifts Delivery Hero Shares

DJ

Citește

25 mai 2026, 21:22 UTC

Câștiguri

Disney's 'Mandalorian and Grogu' Conquers Memorial Day Weekend Box Office -- Barrons.com

DJ

Citește

25 mai 2026, 20:50 UTC

Market Talk
Câștiguri

Basic Materials Roundup: Market Talk

DJ

Citește

25 mai 2026, 16:20 UTC

Market Talk
Câștiguri

Basic Materials Roundup: Market Talk

DJ

Citește

25 mai 2026, 16:01 UTC

Market Talk

China's Crude Imports Pullback Helps Cap Price Upside -- Market Talk

DJ

Citește

25 mai 2026, 14:43 UTC

Market Talk

Oil Unlikely to Fall Significantly Until Hormuz Fully Reopens -- Market Talk

DJ

Citește

25 mai 2026, 14:15 UTC

Market Talk

Crude Futures Retreat As U.S.-Iran Progress Toward Deal -- Market Talk

DJ

Citește

25 mai 2026, 13:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

DJ

Citește

25 mai 2026, 12:58 UTC

Market Talk

Over 60% of Albertans Indicate No Interest in Separation From Canada -- Market Talk

DJ

Citește

25 mai 2026, 12:56 UTC

Market Talk
Câștiguri

Canadian Earnings Lifted by Higher Commodity Prices in Latest Quarter -- Market Talk

DJ

Citește

25 mai 2026, 12:48 UTC

Market Talk

Interest-Rate Cuts Unlikely in 2026 Even if Middle East Conflict Ends -- Market Talk

DJ

Citește

25 mai 2026, 12:48 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

DJ

Citește

25 mai 2026, 12:34 UTC

Market Talk

Dollar Extends Falls on U.S.-Iran Deal Prospects -- Market Talk

DJ

Citește

25 mai 2026, 12:10 UTC

Market Talk
Achiziții, Fuziuni, Preluări

Delivery Hero's Assets Look Strategic -- Market Talk

DJ

Citește

25 mai 2026, 11:00 UTC

Market Talk

Euro, Sterling, Riskier Currencies Rise Versus Weaker Dollar -- Market Talk

DJ

Citește

25 mai 2026, 10:19 UTC

Market Talk

Swiss Franc Rises to Highest in More Than Two Months Vs Euro -- Market Talk

DJ

Citește

25 mai 2026, 10:05 UTC

Câștiguri

Tenaga Nasional: Well-Positioned to Navigate Global Geopolitical Uncertainties

DJ

Citește

25 mai 2026, 10:04 UTC

Câștiguri

Tenaga Nasional: Operational Performance to Remain Resilient in 2026

DJ

Citește

25 mai 2026, 10:03 UTC

Câștiguri

Tenaga Nasional: 1Q Operating Profit Rose on Higher Electricity Demand, Lower Fuel Prices

DJ

Citește

25 mai 2026, 10:02 UTC

Câștiguri

Tenaga Nasional: 1Q Rev Rose on Higher Electricity Sales

DJ

Citește

25 mai 2026, 10:01 UTC

Câștiguri

Tenaga Nasional 1Q Net Up 3.7% on Year

DJ

Citește

25 mai 2026, 10:00 UTC

Câștiguri

Tenaga Nasional 1Q Rev Up 6.6% on Year

DJ

Citește

25 mai 2026, 09:56 UTC

Câștiguri

Tenaga Nasional Malaysia 1st-Quarter 2026 Earnings Summary Table

DJ

Citește

25 mai 2026, 09:56 UTC

Câștiguri

Tenaga Nasional 1Q EPS MYR0.1883

DJ

Citește

25 mai 2026, 09:56 UTC

Câștiguri

Tenaga Nasional 1Q Rev MYR17.1B

DJ

Citește

25 mai 2026, 09:56 UTC

Câștiguri

Tenaga Nasional 1Q Net MYR1.1B

DJ

Citește

25 mai 2026, 09:38 UTC

Market Talk

U.S.-Iran Talks Lifted Sentiment But No Agreement Would Quickly Restore Normal Market Conditions -- Market Talk

DJ

Citește

25 mai 2026, 09:33 UTC

Market Talk

Global Equities Roundup: Market Talk

DJ

Citește

25 mai 2026, 09:33 UTC

Market Talk

India's Gold Import Tax Raise Won't Curb Demand -- Market Talk

DJ

Citește

25 mai 2026, 08:55 UTC

Market Talk

European Energy Stocks Slide on Falling Oil Prices -- Market Talk

DJ

Citește

Comparație

Modificare preț

Incyte Corp Așteptări

Obiectiv de preț

By TipRanks

11.46% sus

Prognoză pe 12 luni

Medie 108.29 USD  11.46%

Maxim 135 USD

Minim 75 USD

În baza a 19 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruIncyte Corp - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

19 ratings

8

Cumpărare

10

Păstrare

1

Vânzare

Ținând cont de 19 analiști care au acordat evaluări ale acțiunilor Incyte Corp - Dist în ultimele 3 luni.

Sentiment

By Acuity

131 / 345 Clasament în Sănătate

Sentimentul știrilor

Evidențe de creștere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Incyte Corp

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation

Alte acțiuni din sector

LLY

Eli Lilly and Co.

1,066.57

↓-0.02%

JNJ

Johnson and Johnson

230.23

↓-1.85%

ABBV

AbbVie Inc

212.63

↓-1.61%

UNH

UnitedHealth Group Inc

377.52

↓-2.74%

AZN

AstraZeneca PLC

187.14

↓-0.06%
help-icon Live chat